Kaye David M, Hoshijima Masahiko, Chien Kenneth R
Heart Failure Research Group, Baker Heart Research Institute, Melbourne, Victoria 8008, Australia.
Annu Rev Med. 2008;59:13-28. doi: 10.1146/annurev.med.59.052407.103237.
Heart failure is a major cardiovascular disease, characterized by considerable morbidity and mortality. Despite major advances in the pharmacotherapy of heart failure, the options for patients with severe end-stage symptoms remain limited. However, recent developments in the identification of the molecular basis for the progressive nature of heart failure have identified a number of potentially important new therapeutic targets. In particular, key components of the cardiomyocyte calcium-handling pathway show characteristic changes in heart failure. A body of research examining the effect of restoration of these defects in experimental models of heart failure, whether in genetically engineered mouse models or by myocardial gene transfer, very strongly supports the calcium-handling pathway as a target for clinical intervention.
心力衰竭是一种主要的心血管疾病，具有相当高的发病率和死亡率。尽管心力衰竭的药物治疗取得了重大进展，但对于有严重终末期症状的患者来说，治疗选择仍然有限。然而，最近在确定心力衰竭进行性本质的分子基础方面的进展，已经确定了一些潜在的重要新治疗靶点。特别是，心肌细胞钙处理途径的关键成分在心力衰竭中表现出特征性变化。大量研究在心力衰竭实验模型中研究恢复这些缺陷的效果，无论是在基因工程小鼠模型中还是通过心肌基因转移，都非常有力地支持将钙处理途径作为临床干预的靶点。
